{
    "clinical_study": {
        "@rank": "163090", 
        "arm_group": [
            {
                "arm_group_label": "ME1111 solution", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Vehicle Solution", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study.\n\n      The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics\n      of ME1111 after repeated daily topical application of ME1111 in a maximal use setting in\n      adults with distal subungual onychomycosis of the toenails."
        }, 
        "brief_title": "Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients", 
        "condition": "Onychomycosis", 
        "condition_browse": {
            "mesh_term": "Onychomycosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female of any race and between the ages of 18 and 70 inclusive\n\n          2. Clinically diagnosed onychomycosis of the target nail\n\n          3. Presence of moderate to severe distal subungual onychomycosis\n\n          4. A positive potassium hydroxide(KOH) microscopy test result\n\n          5. A positive fungal culture for a dermatophyte\n\n          6. Females of childbearing potential must be using a highly effective method of birth\n             control and be willing to remain on the same method of birth control throughout the\n             study\n\n          7. Good general health as determined by the Investigator based on the subject's medical\n             history and physical examination\n\n        Exclusion Criteria:\n\n          1. Clinical significant laboratory abnormalities that would interfere with the conduct\n             or interpretation of the study or jeopardize subject's safety\n\n          2. Subjects with a history of diabetes mellitus\n\n          3. Unwilling to refrain from the use of nail cosmetics such as clear and/or colored nail\n             solutions\n\n          4. Females who are nursing, pregnant, or planning a pregnancy during the study\n\n          5. Failure to complete the specified washout period(s) for the following topical\n             medications: Antifungals drugs within 4 weeks; Anti-inflammatory drugs,\n             corticosteroids, immunomodulators within 2 weeks\n\n          6. Failure to complete the specified washout period(s) for the following systemic\n             medications: Corticosteroids within 2 weeks; Antifungals for treatment of\n             onychomycosis or any antifungal with known activity against dermatophyte within the\n             previous 24 weeks or 5 half-lives of the drug, whichever is longer;  Immunomodulators\n             within 4 weeks\n\n          7. History of cardiac disease and cardiac arrhythmic activity, or prolonged QT interval\n\n          8. Received treatment for any type of cancer within the last 6 months\n\n          9. History of any significant disease or disorder that might put subjects at risk by\n             participating in study or influence results of study\n\n         10. Nail or anatomic abnormalities of the toe\n\n         11. Positive test for HIV, Hepatitis B or Hepatitis C\n\n         12. History of street drug or alcohol abuse\n\n         13. Donated or lost blood or participated in a clinical study which involved the\n             withdrawal of a large volume of blood (500 mL or more), within the last 6-week\n\n         14. Participated in any other trial of an investigational drug or device within 30 days\n             or 5 half-lives of the investigational drug or participation in a research study\n             concurrent with this study\n\n         15. Unable to communicate or cooperate with the Investigator due to comprehension, mental\n             development, or impaired cerebral function\n\n         16. Presence of any underlying disease that the Investigator deems uncontrolled, and\n             poses a concern for the subjects safety while participating on the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841996", 
            "org_study_id": "ME1111-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "ME1111 solution", 
                "description": "Once a day for 28 days", 
                "intervention_name": "ME1111 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle Solution", 
                "description": "Once a day for 28 days", 
                "intervention_name": "Vehicle Solution", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study of the Safety, Absorption and Systemic Pharmacokinetics of ME1111 Topical Agent Applied to All Toenails of Adult Moderate to Severe Onychomycosis Patients for 28 Days", 
        "overall_official": {
            "affiliation": "Meiji Seika Pharma Co., Ltd.", 
            "last_name": "Mitsuharu Egawa", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "The number of adverse events observed throughout the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "from Baseline to Day 57"
            }, 
            {
                "measure": "Application site reactions will be evaluated using categorical scales for signs and symptoms throughout the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "from Baseline to Day 57"
            }, 
            {
                "measure": "Area under the plasma concentration of ME1111 will be assessed based on the analysis of blood samples over 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 28"
            }, 
            {
                "measure": "Urinary excretion rate  will be assessed based on the analysis of urinary samples over 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 28"
            }, 
            {
                "measure": "Plasma trough levels of ME1111", 
                "safety_issue": "No", 
                "time_frame": "Day 4, 8, 15, 22, 25, 43, 57"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the nail concentration of ME1111", 
                "safety_issue": "No", 
                "time_frame": "Day 2, 15, 29, 57"
            }, 
            {
                "measure": "The proportion of subjects who achieve negative KOH microscopy testing results", 
                "safety_issue": "No", 
                "time_frame": "Day 29, 57"
            }, 
            {
                "measure": "The proportion of subjects who achieve negative fungal culture results", 
                "safety_issue": "No", 
                "time_frame": "Day 29, 57"
            }, 
            {
                "measure": "The change from baseline in linear toenail growth at Days 29 and 57 will be analyzed", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 29, 57"
            }
        ], 
        "source": "Meiji Seika Pharma Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meiji Seika Pharma Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}